The PROMiSe trial: baseline data review and progress report.

@article{Wolinsky2004ThePT,
  title={The PROMiSe trial: baseline data review and progress report.},
  author={Jerry S. Wolinsky},
  journal={Multiple sclerosis},
  year={2004},
  volume={10 Suppl 1},
  pages={
          S65-71; discussion S71-2
        }
}
The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer acetate treatment over 3 years in patients with primary progressive multiple sclerosis (PPMS). A total of 943 patients were enrolled, and all those remaining on-study had completed at least 24 months as of October 2002. Baseline clinical and MRI characteristics and select correlations are reported here. A total of 3.9% of patients exhibited confirmed relapse over 1904… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Glatiramer acetate in the treatment of multiple sclerosis

Neuropsychiatric disease and treatment • 2007
View 3 Excerpts
Highly Influenced

Cerebrospinal fluid analysis.

Handbook of clinical neurology • 2014
View 2 Excerpts